Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Daniel Karlin Sells 5,600 Shares of Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the sale, the insider directly owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. The trade was a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Mind Medicine (MindMed) Trading Up 3.1%

Shares of MNMD opened at $13.46 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -6.60 and a beta of 2.57. The stock has a fifty day moving average price of $12.33 and a two-hundred day moving average price of $10.47. Mind Medicine has a 52-week low of $4.70 and a 52-week high of $14.43.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.26). Analysts predict that Mind Medicine will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MNMD. Stoneridge Investment Partners LLC grew its stake in shares of Mind Medicine (MindMed) by 7.5% during the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after purchasing an additional 804 shares during the period. Cerity Partners LLC boosted its holdings in Mind Medicine (MindMed) by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after buying an additional 1,165 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in Mind Medicine (MindMed) by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock worth $106,000 after buying an additional 1,400 shares during the last quarter. Palumbo Wealth Management LLC increased its stake in shares of Mind Medicine (MindMed) by 6.3% in the 2nd quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company’s stock valued at $156,000 after acquiring an additional 1,415 shares during the last quarter. Finally, Creative Planning raised its position in shares of Mind Medicine (MindMed) by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on MNMD shares. Royal Bank Of Canada decreased their price target on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, November 7th. Lifesci Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Tuesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a research note on Wednesday, October 8th. Canaccord Genuity Group upped their price target on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Jones Trading initiated coverage on Mind Medicine (MindMed) in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $30.33.

Key Headlines Impacting Mind Medicine (MindMed)

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM-120 program advancing: MM-120 has moved into Phase III for GAD and MDD with pivotal readouts expected in 2026, a key near-term catalyst that supports upside expectations for revenue-path and valuation. Zacks: MNMD Stock Up, What’s In Store for 2026?
• Positive Sentiment: Broker enthusiasm: JonesTrading and other analysts have recently voiced bullish views on the company’s pipeline and growth prospects, which helps lift sentiment and supports higher target prices. Yahoo Finance: JonesTrading Bullish View
• Neutral Sentiment: Analyst mix and institutional ownership: The stock has multiple buy/strong-buy ratings and a wide range of price targets (MarketBeat shows an average target well above current levels) while hedge funds own ~28% — supportive but mixed signals. MarketBeat: MNMD Analyst and Institutional Data
• Negative Sentiment: Insider selling: Several insiders sold shares on Dec. 26 — CEO Robert Barrow sold 25,791 shares (~$339k), Mark Sullivan sold 11,276 shares (~$148k) and Daniel Karlin sold 5,600 shares (~$73.6k). Each sale reduced their holdings by a few percent; while not enormous relative to total float, clustered insider sales can create near-term selling pressure or prompt re-evaluation by some investors. InsiderTrades: MNMD Insider Selling

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.